Senior Director, Commercial, EU Center

The role

You will build and lead the commercial field team in Germany, Austria, and Switzerland. You will execute strategic initiatives and prepare for launches in ADH1 and achondroplasia.

What you will do

• Build, lead and develop the commercial field team across Germany, Austria and Switzerland
• Own commercial launch plans for ADH1 and achondroplasia and set up a model for future indications
• Adapt global disease awareness and marketing materials to local needs, languages and regulations
• Ensure local execution of HCP service offerings
• Own the local forecast and demand plan and align with Supply Chain and Finance
• Work with Medical Affairs, Market Access and Patient Advocacy to coordinate activities
• Ensure commercial activities comply with HWG, Austrian Medicines Act (AMG), Swiss Therapeutic Products Act (HMG) and industry codes

Required qualifications

• Degree in life sciences, pharmacy, medicine or business
• At least 12 years of commercial experience in pharma or biotech
• At least 5 years leading field teams
• Proven track record of at least one successful launch in Germany
• Solid knowledge of forecasting, demand planning and P&L management
• Knowledge of how pricing and reimbursement (AMNOG, EKO, SL) shape the commercial plan
• Comfortable using digital engagement channels and driving productivity with AI tools
• Fluent German
• Fluent English
• Willingness to travel approximately 50% of the time

Nice to have

• Advanced degree (MBA, PhD, PharmD)
• Experience in rare diseases, endocrinology or pediatrics
• Experience in a rare disease or orphan drug launch
• Experience in Austria and/or Switzerland

Benefits

• Market leading compensation
• Hybrid work model
• Career development through regular feedback, continuous education and professional development programs
• Financial rewards for strong performance
• Peer-to-peer recognition
• Growth opportunities

About the company

BridgeBio uses a moneyball for biotech approach, pooling projects and promising early-stage research from academia to reduce risk and unleash innovation. The company builds bridges to groundbreaking advancements in rare disease and develops medicines for patients with unmet needs.